Inventor · disambiguated record
Catia Traversari
Also filed as: TRAVERSARI CATIA
23 granted patents·2 pending applications·785 citations·filing 1991–2019
97Inventor score
Top patents by PatentIndex Score
25 records- 0196US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0294US5405940AIsolated nonapeptides derived from MAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 1992·Granted Apr 11, 1995·129 cites·9 claims
- 0390US5620886AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1993·Granted Apr 15, 1997·75 cites·13 claims
- 0478US6034214AIsolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cellsLUDWIG INST CANCER RES·Filed 1994·Granted Mar 7, 2000·40 cites·4 claims
- 0578US5462871AIsolated nucleic acid molecules which encode MAGE derived nonapeptidesLUDWIG INST CANCER RES·Filed 1993·Granted Oct 31, 1995·52 cites·16 claims
- 0677US5554506AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Sep 10, 1996·31 cites·3 claims
- 0775US6531451B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1999·Granted Mar 11, 2003·24 cites·2 claims
- 0875US5925729ATumor rejection antigen precursors, tumor rejection antigens and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jul 20, 1999·31 cites·1 claims
- 0972US5695994AIsolated cytolytic T cells specific for complexes of MAGE related peptides and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 9, 1997·20 cites·6 claims
- 1069US6488932B1Method for treating cancer by administering MAGE-derived peptidesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 3, 2002·25 cites·4 claims
- 1169US6201111B1Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1999·Granted Mar 13, 2001·15 cites·1 claims
- 1269US5856091AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Jan 5, 1999·16 cites·21 claims
- 1366US5854203ATumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Dec 29, 1998·25 cites·2 claims
- 1461US7413733B2Antigen transduced T cells used as a delivery system for antigensMOLMED SPA·Filed 2003·Granted Aug 19, 2008·1 cites·11 claims
- 1557US6222012B1Isolated nonapeptides presented by HLA molecules, and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Apr 24, 2001·10 cites·7 claims
- 1657US5837476AMethods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1998·Granted Nov 17, 1998·19 cites·2 claims
- 1755US6353089B1Method for stimulating CTLs with peptidesLUDWIG INST CANCER RES·Filed 1999·Granted Mar 5, 2002·6 cites·4 claims
- 1855US2008286305A1Antigen Transduced T Cells Used as a Delivery System for AntigensMOLMED SPA·Filed 2008·Application pending·0 cites
- 1952US6379901B1Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Apr 30, 2002·12 cites·2 claims
- 2052US6019987AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Feb 1, 2000·7 cites·8 claims
- 2152US6001975APrecursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1998·Granted Dec 14, 1999·15 cites·1 claims
- 2242US2003228308A1Isolated peptides which bind to HLA-Cw6 molecules and uses thereofFiled 2002·Application pending·0 cites
- 2332US12304962B2CAR NK cellsGLYCOSTEM THERAPEUTICS B V·Filed 2019·Granted May 20, 2025·0 cites·12 claims
- 2432US7923534B1Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1997·Granted Apr 12, 2011·0 cites·3 claims
- 2531USRE40089ENucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1996·Granted Feb 19, 2008·0 cites·25 claims
Join the waitlist — get patent alerts
Get an alert when Catia Traversari files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →